SCHEMBL4145606

SCHEMBL4145606

O=C(O)CC(NS(=O)(=O)c1cccc(C(F)(F)F)c1)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 6/20 0.76
NPSR1 Q6W5P4 1/20 0.58
SLC1A3 P43003 1/20 0.57
SLC1A2 P43004 1/20 0.57
ITGB3 P05106 4/20 0.56
ITGAV P06756 4/20 0.56
ATM Q13315 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALDH1A1 P00352 1/20 0.56
MMP7 P09237 1/20 0.54
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP13 P45452 1/20 0.53
BDKRB1 P46663 3/20 0.53
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4141770 0.92 EEF2K (0.64) EEF2KNPSR1SLC1A3SLC1A2ITGB3
SCHEMBL5184370 0.91 EEF2K (0.62) EEF2KNPSR1SLC1A3SLC1A2MMP7
SCHEMBL28408144 0.86 EEF2K (1.00) EEF2KSLC1A3SLC1A2ITGB3ITGAV
SCHEMBL5184456 0.84 NPSR1 (0.62) EEF2KNPSR1SLC1A3SLC1A2ITGB3
SCHEMBL5183729 0.84 NPSR1 (0.62) EEF2KNPSR1SLC1A3SLC1A2ITGB3
SCHEMBL28404274 0.83 ATM (0.76) EEF2KITGB3ITGAVATML3MBTL1
SCHEMBL5183280 0.82 NPSR1 (0.67) EEF2KNPSR1SLC1A3SLC1A2ITGB3
SCHEMBL5184471 0.82 NPSR1 (0.67) EEF2KNPSR1SLC1A3SLC1A2ITGB3
SCHEMBL6772863 0.82 EEF2K (0.66) EEF2KITGB3ITGAVATML3MBTL1
SCHEMBL26920205 0.81 EEF2K (0.65) EEF2KNPSR1SLC1A3SLC1A2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048224-A1 COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2009-02-19 US disclosed
US-7425631-B2 Compounds and methods of use AMGEN INC. (US) 2008-09-16 US disclosed
EP-1631542-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF Amgen, Inc. (US) 2006-03-08 EP disclosed
US-20050124654-A1 Compounds and methods of use AMGEN INC. 2005-06-09 US disclosed
WO-2004092116-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF AMGEN, INC. (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124654-A1 Compounds and methods of use LTC4S, PTGES, LTB4R2 EEF2K 2388/4885NPSR1 661/4885SLC1A3 3416/4885
US-20090048224-A1 COMPOUNDS AND METHODS OF USE LTC4S, PTGES, LTB4R2 EEF2K 2388/4885NPSR1 661/4885SLC1A3 3416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.